Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Nicolas Girerd Added: 1 year ago
HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501).This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients… View more
Author(s): Jasper J Brugts Added: 1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,… View more
Author(s): Jasper J Brugts Added: 1 year ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672). MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of… View more
Author(s): Meng He , Jinwei Zhang , Jianbo Yu , et al Added: 2 days ago
Author(s): William T Abraham , Hanad Bashir Added: 1 year ago
AHA 23 — Dr Hanad Bashir, CardioNerds ambassador, interviews Prof William T Abraham (The Ohio State University, US) on the findings of a clinical evaluation of the Cordio app in adult patients with acute decompensated heart failure.The Cordio "HearO" app (Cordio Medical) uses patient speech sampled via mobile phone to sense fluid accumulation related to chronic heart failure, and provides alerts… View more
Author(s): William Herrington Added: 6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more